Learn more Got it! Publications Zanidatamab VIDEO: Phase 2 Study of Zanidatamab + Chemotherapy in First-line HER2-expressing Gastroesophageal Adenocarcinoma (GEA) (Presented by: Geoffrey Ku, MD; European Society of Medical Oncology Annual Congress, September 16, 2021) Phase (Ph) 2 Study of Zanidatamab + Chemotherapy (chemo) in First Line (1L) HER2 expressing Gastroesophageal Adenocarcinoma (GEA) (European Society for Medical Oncology Congress, September 16, 2021) Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action (American Association for Cancer Research Annual Meeting, April 10, 2021) The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers (American Association for Cancer Research Annual Meeting, April 10, 2021) A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers (BTCs) (American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 15, 2021) Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study (American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 15, 2021) Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study (American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 15, 2021) Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumor (# 61O) (European Society for Medical Oncology Asia Congress, November 22, 2019) ZW49 ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers (San Antonio Breast Cancer Symposium, December 8, 2018) Preclinical Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation (American Association for Cancer Research Annual Meeting, April 10, 2021) ProTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics (American Association for Cancer Research Annual Meeting, April 10, 2021) Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB (American Association for Cancer Research Annual Meeting, April 10, 2021) TECHNOLOGY Azymetric™ ZymeLink™ EFECT™ ProTECT™ Science PIPELINE Zanidatamab ZW49 Preclinical Candidates Partnerships Publications For Patients INVESTORS Stock Info News Releases Events & Presentations Financials Governance CORPORATE Leadership Board of Directors Careers Legal Privacy Contact Twitter LinkedIn